Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mikdadi, Ghiath
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation	Completed	4	339	US	Dronedarone, Multaq	American Heart Association, Duke Clinical Research Institute, Sanofi	Atrial Fibrillation	01/24	06/24
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity	Completed	3	731	US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)	07/24	07/24
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
NCT05412927: AngelMed Guardian® System PMA Post Approval Study	Recruiting	N/A	500	US	PMA P150009 AngelMed Guardian® System	Angel Medical Systems	Acute Coronary Syndrome	12/26	12/26